Updates from the Skunkworks Division
October 12, 2024
Our cross-divisional integration project VISION-2025 has successfully completed phase 3 trials. The project combines bioenhancement, AI, and cybernetics research to create unprecedented human capability enhancements. Full results will be presented at the upcoming Q4 research symposium.
October 5, 2024
Stark Industries has approved a $485M expansion budget for international facility development. New research centers planned for Tokyo, Geneva, Singapore, Tel Aviv, and Dubai will focus on specialized aspects of our research portfolio.
September 28, 2024
Project ORION team achieves major milestone with successful bidirectional neural communication tests. The AI Research team demonstrated real-time thought-to-digital translation with 94% accuracy in controlled trials.
September 10, 2024
Stark Industries has approved $75M in additional funding for bioenhancement research, enabling expansion of Project ORION and related neural interface development.
August 22, 2024
Our new bioenhancement laboratory in Wales is now operational, featuring cutting-edge cellular research capabilities and biosafety level 3 containment facilities.
July 15, 2024
We're pleased to announce Dr. Melinda May has joined Skunkworks to lead our bioenhancement research division. Dr. May brings extensive experience in regenerative medicine and cellular biology.
June 30, 2024
Our cybernetics team successfully demonstrated bidirectional neural control of advanced prosthetic limbs, marking a significant milestone in human-machine integration.